Cryo-Save Group N.V.: Announcement of impairment of

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces a non-cash impairment charge against its goodwill.

The Group has undertaken a prudent review of the projected cash flows, taking into account the lower growth rates in primarily Southern Europe. Based on this review and in accordance with International Financial Reporting Standards (IFRS), this has resulted in a non-cash impairment charge of €14 million against goodwill, which was paid for acquisitions during the period 2008-2011.The impairment charge will be reported in the Group's 2012 financial results.

Arnoud van Tulder, Chief Executive officer, commented:

"It goes without saying that we do regret to announce this non-cash impairment charge.

"We are facing the consequence of the economic downturn which lasts longer than foreseen, especially in countries such as Spain and Italy. Cryo-Save does not expect this accounting write down to affect its current on-going business and financial performance."

Enquiries:

Cryo-Save Group	+ 31 (0) 575 509 100
Arnoud van Tulder, Chief Executive Officer

Daniel Stewart & Company plc (UK)	+ 44 (0) 20 7776 6550
Martin Lampshire

Free footage is available on www.videobankonline.com.

About Cryo-Save (www.cryo-save.com/group)

Cryo-Save, the leading international family stem cell bank, and the largest bank in Europe, stores more than 230,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already over 70 diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents, with ultramodern processing and storage facilities in Arabia, Belgium, Germany, India and South Africa.

Cryo-Save Group N.V.: Announcement of impairment of goodwill

Attachments